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Exosomes are small membrane vesicles secreted from most cell types. They contain a range of proteins, lipids, 
mRNAs and microRNAs (miRNA) and are naturally taken up by cells in order to deliver these contents to 
recipient cells. Increased understanding of this process as well as advances in bioengineering has led to 
investigations into the use of exosomes as targeted vehicles to transport therapeutic non-coding RNAs, proteins 
or drug molecules directly across cellular barriers into recipient cells. miRNAs are small non-coding RNA 
molecules, which play a key role in mediating biological function due to their prominent role in gene regulation. 
Deregulation of miRNAs is a common feature in cancer, suggesting that these molecules could serve as targets 
for therapeutic intervention by restoring or inhibiting their cellular function. However, various biological barriers 
including in vivo nuclease degradation, fibrous nature of tumors, and miRNA-induced immune response 
drastically hinder their bioavailability. In the context of these complex settings, exosomal delivery may display a 
novel strategy for targeted delivery of RNA therapeutics. 
 
We have recently identified and characterized novel pro-apoptotic miRNAs (Kleemann et al 2016, Flum et al 
2017), which are down-regulated in cancer cells suggesting promising potential for therapeutic approaches.  In 
the current study we conducted an initial evaluation of the novel concept to enable targeted delivery of small 
therapeutic RNAs using exosomes as biological transport systems. CEVECs amniocyte production cells (CAP) 
are utile human expression hosts highly suitable for the production of glycosylated biotherapeutic proteins. 
However, there are currently no reports as to whether this human cell line may as well produce extracellular 
vesicles suitable for targeted delivery of therapeutics. In order to evaluate these cells as production hosts for 
exosomes, we initially cultivated parental CAP cells and were able to isolate exosomes by centrifugation. 
Exosomal preparations were examined for vesicle identity, size, morphology and concentration using dynamic 
light scattering, flow cytometry, western blotting and electron microscopy. In order to be able to visualize 
exosomes and track targeted delivery in subsequent experiments, we engineered CAP cells to stably 
overexpress a CD63-GFP-fusion protein. This overexpression of a fluorescent transmembrane protein present 
on exosomes enabled the tracing of produced exosomes using flow cytometry. To functionally analyze isolated 
exosomes regarding their potential to delivery small therapeutic agents, these fluorescently labeled exosomes 
were further engineered to overexpress therapeutic, pro-apoptotic and control miRNAs by stable genome 
integration into CAP parental cells. Resulting preparations of engineered exosomes were analyzed for modified 
miRNA content in comparison to parental cells using qPCR. Currently the cells are further engineered to 
overexpress modified surface receptors to facilitate targeted uptake by tumor cells. Fluorescently labelled 
exosomes carrying therapeutic miRNAs and surface receptors will finally be co-cultured with target cells to 
analyze the potential of engineered exosomes to crossing membrane barriers and reliably deliver therapeutic 
miRNAs to recipient cells.  
The current study pursues the novel therapeutic concept of using exosomes as delivery vehicle for small non-
coding RNAs molecules. We present data which assess for the first time the potential application of exosomes 
produced by a human production host for biotherapeutics. In addition to these current engineering and delivery 
approaches, future application of this cell therapy will heavily depend upon mass production of these delivery 
vectors and production issues will therefore gain increasing importance. 
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